The AEGEAN trial demonstrated a clinically meaningful improvement in EFS with the addition of perioperative durvalumab to neoadjuvant chemotherapy, alongside significantly improved pathological complete response and major pathological response . Understanding surgical outcomes can further inform the use of this treatment and is an important consideration for patients and physicians,"
The AEGEAN trial is a double-blind, placebo-controlled phase 3 study that evaluated the use of perioperative durvalumab in combination with neoadjuvant chemotherapy compared to neoadjuvant chemotherapy alone. The trial involved adults with treatment-naïve resectable NSCLC and ECOG PS 0/1. Patients were randomized to receive either neoadjuvant durvalumab 1500 mg or placebo intravenously alongside platinum-based CT prior to surgery.
Lobectomy, sleeve resection, or bilobectomy were allowed as planned surgery ; the protocol was amended with enrollment ongoing to exclude patients with tumors classified as T4 for any reason other than size or whose planned surgery was pneumonectomy .
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study provides new hope for patients with stage III EGFR-mutant non-small cell lung cancerThe immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.
Source: NewsMedical - 🏆 19. / 71 Read more »
Stigmatization of smoking-related diseases is a barrier to care, and the problem may be on the riseThe stigma that patients face when diagnosed with lung cancer is associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: medical_xpress - 🏆 101. / 51 Read more »
Study aims to identify interventions to combat stigma associated with lung cancer and smoking-related respiratory diseasesThe stigma that patients face when diagnosed with lung cancer is associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: NewsMedical - 🏆 19. / 71 Read more »
Adagrasib shows durable clinical activity in KRAS-G12C-mutated NSCLCThe oral, selective KRAS G12C inhibitor The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: NewsMedical - 🏆 19. / 71 Read more »
Exhaled breath analysis shows promise in detecting malignant pleural mesotheliomaIdentifying and analyzing volatile organic compounds in exhaled breath of patients with malignant pleural mesothelioma showed promise as a screening method for MPM, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: medical_xpress - 🏆 101. / 51 Read more »
Six-year follow-up data on survival, benefits for patients with metastatic NSCLC and nivolumab + ipilimumab treatmentResearch findings from the CheckMate 227 trial will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore, shedding light on the six-year survival and quality of life benefits associated with first-line nivolumab + ipilimumab therapy.
Source: medical_xpress - 🏆 101. / 51 Read more »